Data from Pharmawand - Curated by EPG Health - Date added 10 February 2019

Alnylam Pharmaceuticals, Inc.announced hat results from the Phase 1 study of givosiran, an investigational, subcutaneous RNAi therapeutic targeting aminolevulinic acid synthase 1 (ALAS1) for the treatment of acute hepatic porphyria (AHP), were published online in The New England Journal of Medicine (NEJM). The full manuscript, titled “Phase 1 Trial of an RNA Interference Therapy for Acute Intermittent Porphyria,” appeared in the February 7, 2019 issue of NEJM.

In the Phase 1 study, the proportion of patients reporting adverse events (AEs) was similar across treatment groups with no clear relationship with givosiran dose. The majority of AEs were mild or moderate; the most common AEs included nasopharyngitis, abdominal pain, and diarrhea. Serious AEs (SAEs) were reported in six patients treated with givosiran (N=33), including – as previously reported – one fatal SAE of hemorrhagic pancreatitis, assessed as unlikely related to study drug by the study investigator.

Additional unrelated SAEs included influenza infection, opioid bowel dysfunction, miscarriage, and two patients with abdominal pain. No SAEs were reported in the placebo group (N=10). Results showed that basal ALAS1 messenger RNA (mRNA), aminolevulinic acid (ALA), and porphobilinogen (PBG) levels were associated with disease activity, with higher levels noted in those with recurrent attacks, confirming the central importance of liver ALAS1 induction and ALA and PBG in the pathophysiology of acute intermittent porphyria (AIP). Monthly givosiran administration resulted in sustained reductions of ALAS1 mRNA, urinary ALA, and PBG to near normal levels. In exploratory analyses, these reductions were associated with a 79 percent decrease in mean annualized attack rate and an 83 percent decrease in mean annualized hemin usage, compared with placebo.

See- "Phase 1 Trial of an RNA Interference Therapy for Acute Intermittent Porphyria"_Eliane Sardh, M.D., Ph.D., Pauline Harper, M.D., Ph.D., Manisha Balwani, M.D., Penelope Stein, M.D., Ph.D., et al.-February 7, 2019. N Engl J Med 2019; 380:549-558 DOI: 10.1056/NEJMoa1807838.


You will need to login, to leave a comment. is not monitored for collection of adverse event reports. Any adverse events should be reported to your national reporting agency and/or the manufacturer.

Learning Zones

An Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Acute and Advanced Heart Failure

Acute and Advanced Heart Failure

What are the most effective treatments for acute heart failure? Can you define advanced heart failure? Discover here...

+ 3 more

Allergic Rhinitis

Allergic Rhinitis

Allergic rhinitis causes great strain on the workforce. Help to reduce sick days and improve productivity with appropriate treatment options.

+ 4 more

Anticoagulation Therapy for Stroke Prevention

Anticoagulation Therapy for Stroke Prevention

Anticoagulation therapy for Stroke Prevention Learning Zone offers a deep-dive into atrial fibrillation causes, consequences, diagnosis and management to help you deliver optimal care and prevent strokes in patients living with this common arrhythmia.

Load more

Related Content